Myra Vision develops a treatment that allows maximum IOP reduction for patients with moderate to severe glaucoma.
Myra Vision has raised $25.0M in total funding. The most recent round was Series B. The last funding was announced in June 2023.
Myra Vision's investors include Cormorant Asset Management, Shifamed, The Capital Partnership, PA MedTech VC Fund.
Myra Vision is headquartered in Campbell, United States.
Myra Vision develops a treatment that allows maximum IOP reduction for patients with moderate to severe glaucoma.
Myra Vision is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Myra Vision — Funding & Investors." VCBacked, June 26, 2023, https://www.vcbacked.co/company/myra-vision. Accessed July 19, 2026.
VCBacked. (2023). Myra Vision — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/myra-vision
{{cite web |title=Myra Vision — Funding & Investors |url=https://www.vcbacked.co/company/myra-vision |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated